Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Delanzomib in Relapsed/Refractory Multiple Myeloma
NCT01023880Phase 2Terminated
- Sponsor
- Cephalon, Inc.
- Start
- Jan 2010
- Primary completion
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of delanzomib in multiple myeloma (MM), sponsored by Cephalon, Inc.. Started Jan 2010; status: terminated.
02
Drugs
delanzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01023880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01023880.